R.H. Bluestein & Co’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $930K | Sell |
24,000
-50
| -0.2% | -$2.01K | 0.06% | 97 |
|
|
2022
Q2 | $896K | Hold |
24,050
| – | – | 0.06% | 108 |
|
|
2022
Q1 | $1.06M | Hold |
24,050
| – | – | 0.04% | 106 |
|
|
2021
Q4 | $1.02M | Hold |
24,050
| – | – | 0.04% | 110 |
|
|
2021
Q3 | $1.04M | Hold |
24,050
| – | – | 0.04% | 108 |
|
|
2021
Q2 | $1.03M | Sell |
24,050
-150
| -0.6% | -$6.31K | 0.04% | 119 |
|
|
2021
Q1 | $935K | Hold |
24,200
| – | – | 0.04% | 110 |
|
|
2020
Q4 | $870K | Hold |
24,200
| – | – | 0.04% | 113 |
|
|
2020
Q3 | $925K | Sell |
24,200
-100
| -0.4% | -$3.85K | 0.05% | 99 |
|
|
2020
Q2 | $853K | Sell |
24,300
-4,700
| -16% | -$169K | 0.05% | 106 |
|
|
2020
Q1 | $946K | Buy |
29,000
+5,000
| +21% | +$195K | 0.08% | 79 |
|
|
2019
Q4 | $1.08M | Sell |
24,000
-500
| -2% | -$20.9K | 0.05% | 76 |
|
|
2019
Q3 | $997K | Hold |
24,500
| – | – | 0.06% | 72 |
|
|
2019
Q2 | $1.05M | Hold |
24,500
| – | – | 0.06% | 69 |
|
|
2019
Q1 | $940K | Hold |
24,500
| – | – | 0.05% | 74 |
|
|
2018
Q4 | $866K | Sell |
24,500
-10,000
| -29% | -$363K | 0.07% | 59 |
|
|
2018
Q3 | $1.33M | Sell |
34,500
-7,150
| -17% | -$250K | 0.06% | 67 |
|
|
2018
Q2 | $1.36M | Buy |
41,650
+150
| +0.4% | +$4.52K | 0.07% | 58 |
|
|
2018
Q1 | $1.13M | Buy |
41,500
+11,500
| +38% | +$313K | 0.06% | 79 |
|
|
2017
Q4 | $744K | Sell |
30,000
-48,900
| -62% | -$1.35M | 0.04% | 109 |
|
|
2017
Q3 | $2.3M | Buy |
78,900
+23,900
| +43% | +$660K | 0.13% | 55 |
|
|
2017
Q2 | $1.52M | Buy |
55,000
+24,500
| +80% | +$650K | 0.09% | 57 |
|
|
2017
Q1 | $759K | Sell |
30,500
-2,040
| -6% | -$49.6K | 0.05% | 101 |
|
|
2016
Q4 | $704K | Sell |
32,540
-8,615
| -21% | -$188K | 0.05% | 99 |
|
|
2016
Q3 | $979K | Sell |
41,155
-1,375,739
| -97% | -$32.8M | 0.06% | 63 |
|
|
2016
Q2 | $33.1M | Buy |
1,416,894
+333,946
| +31% | +$7.22M | 2.54% | 19 |
|
|
2016
Q1 | $20.4M | Sell |
1,082,948
-141,549
| -12% | -$2.49M | 1.47% | 31 |
|
|
2015
Q4 | $22.6M | Buy |
1,224,497
+349,842
| +40% | +$6.27M | 1.41% | 33 |
|
|
2015
Q3 | $14.4M | Sell |
874,655
-14,520
| -2% | -$248K | 1.02% | 40 |
|
|
2015
Q2 | $15.7M | Buy |
889,175
+191,010
| +27% | +$3.41M | 0.96% | 41 |
|
|
2015
Q1 | $12.4M | Buy |
698,165
+662,060
| +1,834% | +$10.5M | 0.75% | 45 |
|
|
2014
Q4 | $478K | Sell |
36,105
-13,300
| -27% | -$170K | 0.03% | 184 |
|
|
2014
Q3 | $583K | Sell |
49,405
-11,400
| -19% | -$144K | 0.04% | 175 |
|
|
2014
Q2 | $776K | Sell |
60,805
-38,195
| -39% | -$497K | 0.05% | 144 |
|
|
2014
Q1 | $1.34M | Sell |
99,000
-110,100
| -53% | -$1.45M | 0.09% | 88 |
|
|
2013
Q4 | $2.51M | Sell |
209,100
-114,400
| -35% | -$1.35M | 0.16% | 64 |
|
|
2013
Q3 | $3.8M | Buy |
323,500
+81,750
| +34% | +$884K | 0.27% | 58 |
|
|
2013
Q2 | $2.24M | Buy |
+241,750
| New | +$2.05M | 0.2% | 61 |
|
Other funds holding BSX
BG
R.H. Bluestein & Co's BSX Position: Q3 2022 in Review
R.H. Bluestein & Co reduced its Boston Scientific (BSX) stake by 0.21% in Q3 2022, selling an estimated $2.01K and leaving 24,000 shares worth $930K. The position accounts for 0.06% of the portfolio, ranked #97.
R.H. Bluestein & Co first reported a position in BSX in Q2 2013 and has held it in 38 quarters since. The position peaked at $33.1M in Q2 2016. 864 funds tracked by Wall St. Rank hold BSX as of Q3 2022.
- R.H. Bluestein & Co held 24,000 shares of Boston Scientific worth $930K as of Q3 2022.
- R.H. Bluestein & Co sold 50 Boston Scientific shares in Q3 2022, an estimated $2.01K.
- Boston Scientific made up 0.06% of R.H. Bluestein & Co's portfolio in Q3 2022, its #97 holding.
- R.H. Bluestein & Co first reported a position in Boston Scientific in Q2 2013 and has held it in 38 quarters since.
- R.H. Bluestein & Co's Boston Scientific position peaked at $33.1M in Q2 2016.
- 864 funds tracked by Wall St. Rank held Boston Scientific as of Q3 2022.
Based on R.H. Bluestein & Co's 13F filing for Q3 2022, filed 14 Nov 2022.